DNA.US Ginkgo Bioworks Holdings

Healthcare Biotechnology USA Stocks
11.55 USD
Close of Nov 14, 2026
5.37 18.22
Market cap
USD 623M
P/E
-
P/B
1.69x
ROE
-57.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DNA.US undervalued?

Graham number

The Graham number of Ginkgo Bioworks Holdings cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ginkgo Bioworks Holdings fundamental analysis

No fundamental analysis for Ginkgo Bioworks Holdings yet.

Ginkgo Bioworks Holdings stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platf…

Full company profile